Using translational medicine to understand clinical differences between botulinum toxin formulations

European Journal of Neurology

Volumn 13, Issue SUPPL. 4, 2006, Pages 10-19

  Aoki, K R ^a   Ranoux, D ^b   Wissel, J ^c  

^a ALLERGAN INC   (United States)

^b CENTRE HOSPITALIER SAINTE ANNE   (France)

^c Neurological Rehabilitation Clinic   (Germany)

Author keywords

BOTOX ; Botulinum toxin; Distal migration; Dose ratios; Dysport ; Formulation; Myobloc ; Xeomin

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; XEOMIN;

ARTICLE; ASTHENIA; BLEPHAROSPASM; CLINICAL STUDY; CLINICAL TRIAL; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG SURVEILLANCE PROGRAM; DRUG SYNTHESIS; DYSPHAGIA; DYSPHONIA; DYSTONIA; ESOPHAGUS ACHALASIA; HEMIFACIAL SPASM; HUMAN; LOW DRUG DOSE; MUSCLE RELAXATION; MUSCLE WEAKNESS; NONHUMAN; PRIORITY JOURNAL; PTOSIS; SEROTYPE; SPASTICITY; TORTICOLLIS; VISUAL DISORDER; XEROSTOMIA;

ANIMALS; BOTULINUM TOXIN TYPE A; BOTULINUM TOXINS; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; SEROTYPING; THERAPEUTIC EQUIVALENCY;

EID: 33750977861     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2006.01649.x     Document Type: Article

References (54)

1. Aoki KR. Botulinum toxin: a successful therapeutic protein. Current Medicinal Chemistry 2004; 11: 3085-3092.
2. Daniels-Holgate PU, Dolly JO. Productive and non-productive binding of botulinum neurotoxin A to motor nerve endings are distinguished by its heavy chain. Journal of Neuroscience Research 1996; 44: 263-271.
3. Dong M, Richards DA, Goodnough MC, Tepp WH, Johnson EA, Chapman ER. Synaptotagmins I and II entry of botulinum neurotoxin B into cells. Journal of Cell Biology 2003; 162: 1293-1303.
4. Dong M, Yeh F, Tepp WH, et al. SV2 is the Protein receptor for botulinum neurotoxin A. Science 2006; 28: 592-596.
5. Mahrhold S, Rummel A, Bigalke H, Davletov B, Binz T. The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Letters 2006; 580: 2011-2014.
6. Nishiki T, Kamata Y, Nemoto Y, et al. Identification of protein receptor for clostridium botulinum type B neurotoxin in rat brain synaptosomes. Journal of Biological Chemistry 1994; 269: 10498-10503.
7. Poulain B, Wadsworth JDF, Shone CC, et al. Multiple domains of botulinum neurotoxin contribute to its inhibition of transmitter release in Aplysia neurons. Journal of Biological Chemistry 1989; 264: 21928-21933.
8. Simpson LL. Identification of the major steps in botulinum toxin action. Annual Review of Pharmacology and Toxicology 2004; 44: 167-193.
9. Simpson L. Pharmacological studies on the cellular and subcellular effects of botulinum toxin. In: Lewis GE ed. Biomedical Aspects of Botulism. New York: Academic Press, 1981: 35-46.
10. Simpson LL. Current concepts on the mechanism of action of clostridial neurotoxins. In: DasGupta BR, ed. Botulinum and Tetanus Neurotoxins: Neurotransmission and Biomedical Aspects. New York: Plenum Press, 1993: 5-15.
11. Naumann M, Jankovic J. Safety of botulinum toxin type A: a systematic review and meta-analysis. Current Medical Research and Opinion 2004; 20: 981-990.
12. Schantz EJ, Johnson EA. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiological Reviews 1992; 56: 80-99.
13. Hambleton P. Clostridium botulinum toxins: a general review of involvement in disease, structure, mode of action and preparation for clinical use. Journal of Neurology 1992; 239: 16-20.
14. Inoue K, Fujinaga Y, Watanabe T, et al. Molecular composition of clostridium botulinum type A progenitor toxins. Infection and Immunity 1996; 64: 1589-1594.
15. Johnson EA, Bradshaw M. Clostridium botulinum and its neurotoxins: a metabolic and cellular perspective. Toxicon 2001; 39: 1703-1722.
16. 125I-botulinum- free neurotoxin: time course of tissue distribution. Toxicon 2003; 42: 461-469.
17. Hambleton P, Capel B, Bailey N, et al. Production, purification and toxoiding of clostridium botulinum type A toxin. In: Lewis GE ed. Biomedical Aspects of Botulism. New York: Academic Press, 1981: 247-260.
18. Aoki KR. Pre-clinical update on botox (botulinum toxin type A) purified neurotoxin complex relative to other neurotoxin preparations. European Journal of Neurology 1999; 6(Suppl. 4): S3-S10.
19. Aoki KR. Botulinum neurotoxin serotypes A and B preparations have different safety margins in pre-clinical models of muscle weakening efficacy and systemic safety. Toxicon 2002; 40: 923-928.
20. Aoki KR, Satorius A, Ardila C, et al. Pharmacology of BOTOX, Dysport, Myobloc and BTX-A in animal models of efficacy and safety. Neurotoxin Research 2006; 9: 236, abstract P50.
21. Aoki R, Francis J, Reynolds H, Leumer D. Comparison of the therapeutic windows of different botulinum neurotoxin preparations in an animal model. Neurology 2003b; 60(Suppl. 1): A212-A213.
22. Aoki KR. A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. Toxicon 2001; 39: 1815-1820.
23. Black JD, Dolly JO. Interaction of I125-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for type A and B on motor nerves. Journal of Cell Biology 1986a; 103: 521-534.
24. Black JD, Dolly JO. Interaction of 1251-labeled botulinum neurotoxins with nerve terminals: II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis. Journal of Cell Biology 1986b; 103: 535-544.
25. Black JD, Dolly JO. Selective location of acceptors for botulinum neurotoxin A in the central and peripheral nervous systems. Neuroscience 1987; 32: 767-769.
26. Dolly JO, Black J, Williams RS, Melling J. Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalisation. Nature 1984; 307: 457-460.
27. Aoki KR. Pharmacology and immunology of botulinum toxin type A. Clinics in Dermatology 2003a; 21: 476-480.
28. Lange DJ, Rubin M, Greene PE, et al. Distant effects of locally injected botulinum toxin: a double-blind study of single fiber EMG changes. Muscle and Nerve 1991; 14: 672-675.
29. Olney RK, Aminoff MJ, Gelb DJ, Lowenstein DH. Neuromuscular effects distant from the site of botulinum neurotoxin injection. Neurology 1988; 38: 1780-1783.
30. Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. European Journal of Neurology 2001; 8(Suppl. 5): 21-29.
31. Clarke CE. Therapeutic potential of botulinum toxin in neurological disorders. Quarterly Journal of Medicine 1992; 82: 197-205.
32. Brin MF, Blitzer A. Botulinum toxin: dangerous terminology errors. Journal of the Royal Society of Medicine 1993; 86: 493-494.
33. Lowe NJ. Botulinum toxin type A for facial rejuvenation. United States and United Kingdom perspectives. Dermatologic Surgery 1998; 24: 1216-1218.
34. Rasmussen LN. Botulinum toxin. Use in the treatment of spasticity in children. Ugeskr for Laeger 2000; 162: 6557-6561.
35. Royal College of Physicians. Guidelines for the use of botulinum toxin (BTX) in the management of spasticity in adults. Concise Guidance to Good Practice July 2002; 1-17.
36. Bihari K. Safety, effectiveness and duration of effect of BOTOX compared with Dysport for blepharospasm, cervical dystonia and hemifacial spasm. Current Medical Research and Opinion 2005; 21: 433-438.
37. Nussgens Z, Roggenkamper P. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefe's Archive for Clinical and Experimental Ophthalmology 1997; 235: 197-199.
38. Sampaio C, Ferreira JJ, Simoes F, et al. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A - Dysport and Botox - assuming a ratio of 4:1. Movement Disorders 1997; 12: 1013-1018.
39. Fahn S. Clinical variants of idiopathic torsion dystonia. Journal of Neurology Neurosurgery and Psychiatry 1989; Jun;(Suppl): 96-100.
40. Odergren T, Hjaltason H, Kaakkola S, et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. Journal of Neurology, Neurosurgery and Psychiatry 1998; 64: 6-12.
41. Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. Journal of Neurology, Neurosurgery, and Psychiatry 2002; 72: 459-462.
42. Benecke R, Jost WH, Kanovsky P, Ruzicka E, Comes G, Grafe S. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 2005; 64: 1949-1951.
43. Roggenkamper P, Jost WH, Bihari K, Comes G, Grafe S for the NT 201 Blepharospasm Study Team Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. Journal of Neural Transmitters 2006; 113: 303-312.
44. Jost WH, Kohl A, Brinkmann S, Comes G. Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteers. Journal of Neural Transmission 2005; 112: 905-913.
45. National Health Surveillance Agency (Brazil) http://www.anvisa.gov.br.
46. World Health Organization http://www.who.int.
47. Marion MH, Sheehy M, Sangla S, Soulayrol S. Dose standardisation of botulinum toxin (letter). Journal of Neurology, Neurosurgery and Psychiatry 1995; 59: 102-103.
48. Durif D. Clinical bioequivalence of the current commercial preparations of botulinum toxin. European Journal of Neurology 1995; 2: 17-18.
49. Vanden Bergh PY, Lison DF. Dose standardization of botulinum toxin. Advances in Neurology 1998; 78: 231-235.
50. Annese V, Bassotti G, Coccia G, et al. Comparison of two different formulations of botulinum toxin A for the treatment of oesophageal achalasia. The Gismad Achalasia Study Group. Alimentary Pharmacology and Therapeutics 1999; 13: 1347-1350.
51. Bhakta BB, Cozens JA, Bamford JM, Chamberlain MA. Use of botulinum toxin in stroke patients with severe upper limb spasticity. Journal of Neurology, Neurosurgery and Psychiatry 1996; 61: 30-35.
52. Bhaumik S, Behari M. Botulinum toxin A-injection for cervical dystonia. Journal of the Association of Physicians of India 1999; 47: 267-270.
53. Hesse S, Brandi-Hesse B, Bardeleben A, Werner C, Funk M. Botulinum toxin A treatment of adult upper and lower limb spasticity. Drugs and Ageing 2001; 18: 255-262.
54. Marchetti A, Magar R, Findley L, et al. Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the real dose study. Movement Disorders 2005; 20: 937-944.